EpiPen®: Important update from Mylan UK regarding the availability of the EpiPen® 0.15mg and 0.3mg adrenaline auto-injectors

23 Apr 2020

Mylan UK has issued an important statement today (23/4/20) regarding the availability of EpiPen® 0.15mg and 0.3mg adrenaline auto-injectors, and extended use beyond labelled expiry date for specific lots (listed in the full statement) of EpiPen® 0.3mg adrenaline auto-injectors.

 

Key points

  • The prescription validation process previously in place no longerapplies, and the limit of two pens per prescription has now been lifted.
  • Pharmacies are able to place orders for EpiPen® Jr 0.15mg and EpiPen®3mg AAI devices through Alliance Healthcare, stating your pharmacy account number in the request.

The full statement also contains important information about extended use beyond labelled expiry date for specific lots of EpiPen® 0.3mg adrenaline auto-injectors, including the list of lot numbers affected. At the end of the extended use period (the end of the month listed under “Extended Expiry Date” in the table of lot numbers found in the full statement), patients will still need to obtain new auto-injector(s) through the usual route.

Read the full statement at http://www.epipen.co.uk/.  

General information for healthcare professionals to assist you in supporting patients is available from http://www.epipen.co.uk/hcp/.  

If you continue to experience problems with the availability of EpiPen®, please could you let us know by email to pharmacyservices@npa.co.uk. Please state your member number, pharmacy details, your geographical area, which strength(s) of EpiPen® you tried to order, and quantity ordered.